Gilead Sciences | GILD - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
ALKERMES USD 20.89M 8.62M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Bristol-Myers Squibb USD 411M 21M 2026-03
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 569K 13K 2026-03
J&J USD 43M 25M 2026-03
Merck USD 479M 67M 2026-03
Moderna USD 11.49B 36B 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 343M 39M 2026-03
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12